Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment
The tumor shrinkage effect of gemcitabine is considered to be limited in cases of advanced gallbladder cancer, and there are few reports of complete response to gemcitabine therapy in patients with this cancer. Therefore, the treatment continuation strategy in these patients, after a complete respon...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2013-10-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/356080 |
| _version_ | 1818141105963663360 |
|---|---|
| author | Koichi Suyama Masafumi Ikeda Eiichiro Suzuki Motohiro Kojima Shuichi Mitsunaga Satoshi Shimizu Izumi Ohno Hideaki Takahashi Hiroyuki Okuyama Akiko Kuwahara Takuji Okusaka Junji Furuse |
| author_facet | Koichi Suyama Masafumi Ikeda Eiichiro Suzuki Motohiro Kojima Shuichi Mitsunaga Satoshi Shimizu Izumi Ohno Hideaki Takahashi Hiroyuki Okuyama Akiko Kuwahara Takuji Okusaka Junji Furuse |
| author_sort | Koichi Suyama |
| collection | DOAJ |
| description | The tumor shrinkage effect of gemcitabine is considered to be limited in cases of advanced gallbladder cancer, and there are few reports of complete response to gemcitabine therapy in patients with this cancer. Therefore, the treatment continuation strategy in these patients, after a complete response has been achieved, still remains to be established. Here, we present the case of a 77-year-old patient with unresectable gallbladder cancer, who after showing complete response to gemcitabine monotherapy administered for 5 years, showed early relapse within only 11 months of discontinuation of the drug. Thus, it is necessary to establish a suitable treatment continuation strategy for patients who show complete response to gemcitabine treatment. |
| first_indexed | 2024-12-11T10:54:36Z |
| format | Article |
| id | doaj.art-0207c8cee00245f8971c82745cfbcd95 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-11T10:54:36Z |
| publishDate | 2013-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-0207c8cee00245f8971c82745cfbcd952022-12-22T01:10:09ZengKarger PublishersCase Reports in Oncology1662-65752013-10-016353153710.1159/000356080356080Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the TreatmentKoichi SuyamaMasafumi IkedaEiichiro SuzukiMotohiro KojimaShuichi MitsunagaSatoshi ShimizuIzumi OhnoHideaki TakahashiHiroyuki OkuyamaAkiko KuwaharaTakuji OkusakaJunji FuruseThe tumor shrinkage effect of gemcitabine is considered to be limited in cases of advanced gallbladder cancer, and there are few reports of complete response to gemcitabine therapy in patients with this cancer. Therefore, the treatment continuation strategy in these patients, after a complete response has been achieved, still remains to be established. Here, we present the case of a 77-year-old patient with unresectable gallbladder cancer, who after showing complete response to gemcitabine monotherapy administered for 5 years, showed early relapse within only 11 months of discontinuation of the drug. Thus, it is necessary to establish a suitable treatment continuation strategy for patients who show complete response to gemcitabine treatment.http://www.karger.com/Article/FullText/356080GemcitabineChemotherapyComplete responseEarly relapseGallbladder cancer |
| spellingShingle | Koichi Suyama Masafumi Ikeda Eiichiro Suzuki Motohiro Kojima Shuichi Mitsunaga Satoshi Shimizu Izumi Ohno Hideaki Takahashi Hiroyuki Okuyama Akiko Kuwahara Takuji Okusaka Junji Furuse Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment Case Reports in Oncology Gemcitabine Chemotherapy Complete response Early relapse Gallbladder cancer |
| title | Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment |
| title_full | Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment |
| title_fullStr | Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment |
| title_full_unstemmed | Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment |
| title_short | Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment |
| title_sort | early relapse of unresectable gallbladder cancer after discontinuation of gemcitabine monotherapy administered for 5 years in a patient who had complete response to the treatment |
| topic | Gemcitabine Chemotherapy Complete response Early relapse Gallbladder cancer |
| url | http://www.karger.com/Article/FullText/356080 |
| work_keys_str_mv | AT koichisuyama earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT masafumiikeda earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT eiichirosuzuki earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT motohirokojima earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT shuichimitsunaga earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT satoshishimizu earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT izumiohno earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT hideakitakahashi earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT hiroyukiokuyama earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT akikokuwahara earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT takujiokusaka earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment AT junjifuruse earlyrelapseofunresectablegallbladdercancerafterdiscontinuationofgemcitabinemonotherapyadministeredfor5yearsinapatientwhohadcompleteresponsetothetreatment |